anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The basis of the proposed study is to determine the clinical outcomes following lateral patellar dislocation (LPD). Despite surgical and non-surgical interventions, young athletes are at high risk for sustaining subsequent dislocations that magnify the effects of disability. It is suspected that if athletes return to high-level activities and expose their knees to substantial forces without normalized movement strategies, then this may increase the risk for future joint injury. Currently, there are no evidence-based criteria to determine an athlete's readiness for sports activity following LPD. The purpose of this study is to characterize clinical outcomes, function, and neuromuscular control strategies employed by athletes following LPD at the time when they are returning to sports participation.

A prospective, longitudinal study design will be utilized. A cohort of up to 100 athletes (ages 12 - 25 years) who have sustained LPD during sports activities that require jumping, cutting, or pivoting maneuvers will be consecutively recruited from the offices of local orthopaedic surgeons, primary care physicians, and sports physical therapists for this study. Investigators will target a subset of surgically managed athletes and a subset of non-surgically managed athletes with LPD. A cohort of up to 100 individuals without history of knee injury will be recruited from local schools and universities to serve as control participants. Data will be collected to evaluate clinical outcomes, thigh and hip strength, lower body function, balance and neuromuscular control strategies. Clinical outcomes will be assessed using self-report questionnaires and performance-based measures, including hop and agility tests. Thigh and hip strength will be assessed utilizing an isokinetic dynamometer. Lower body function will be assessed using a series of single-leg and double-leg hopping tests. Balance will be assessed utilizing a clinical lower extremity reach test. Neuromuscular control will be evaluated by 3-D motion analysis during running, jumping, and cutting activities. Overall, this study will provide a comprehensive evaluation of athletes following LPD. It will provide important information for the future development of rehabilitation approaches that may maximize clinical outcomes for the at risk population.
Provided herein are radiopharmaceutical conjugate compositions and uses thereof. In one aspect, provided herein are conjugates that comprise a monocyclic peptide of 5 to 40 amino acid residues and a metal chelator configured to bind with a radionuclide. In some embodiments, the monocyclic peptide is cyclized by a non-disulfide bond. In some embodiments, the monocyclic peptide does not comprise any non-disulfide bond. The monocyclic peptide can be configured to bind with a structure on a cell. Further provided herein are methods of treating cancer by administering the described conjugates and compositions.
A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
The participants in the conventional electroacupuncture group will select RN3 (Zhongji), CV4 (Guanyuan), and ST28 (Shuidao, both sides), KL3 (Taixi).A needle measuring 0.25×40 mm will be inserted perpendicularly to a depth of 25- 40 mm to RN3, CV4 and ST28 and 0.5 cun to KL3 to induce a local sensation (distention or sourness).Subsequently, the electrodes from the SDZ-IIB electroacupuncture device will be connected to the needles at these points, with the anode connected to ST28 and RN3, the cathode connected to ST28 and CV4. The protocol includes the same duration, frequency of sessions and the parameter setting of electroacupuncture as for the'four sacral points'treatment.
Increase the temperature operating range of ETCO measurements to 5 to 45°C. The signal output-to-CO (carbon monoxide) concentration correlation of the CO sensor is dependent on temperature. The new algorithm will be a different approach because the current algorithm is at the limits of its capability. We will establish the new specifications by determining performance in a bench model under simulated temperature conditions. We will then determine the ability of the modified device to distinguish between SCD and healthy controls. During this initial testing, we will examine the validity of ETCO measurements under regulated room temperature in the hospital setting. We will enroll 20 subjects, 10 each in the SCD arm and control arm to determine the mean and variance of the ETCO values.
The present invention provides a production method of microcapsule nutritious vegetable powder. Vegetable raw materials are prepared into a product through enzyme eradication, expressed juice, high pressure homogeneous squashing, vacuum concentration, spray granulating, freeze drying and packaging. Vegetables produced by the method of the present invention have high solid content, and the product comprises various rich vitamins and mineral substances; the product adopts a microcapsule embedding technique, and the nutrient components, bioactivity, food color and aroma, etc. in the natural vegetables are kept effectively. The product is treated by a high-pressure homogenizing machine, the particle size is less than 5 mu m, and the absorption rate and the degree of effective components are improved greatly. The product has bright color and unique vegetable aroma, and the product is easy to make a person have an edible desire. The microcapsule which forms in a circle has smooth surface, favorable appearance and favorable mouth feel.
The invention discloses a diabetes acupoint therapy sugar conversion paste. The diabetes acupoint therapy sugar conversion paste consists of a zinc oxide adhesive tape 1, a magnetic suspension ring 2, a medicine 3, a non-woven fabric 4, a covering film 5, a magnetic sheet 6 and a magnetic ring 7. The magnetic suspension ring 2 comprises the magnetic ring 7 with the magnetic sheet 6 at the center. One surface of the magnetic suspension ring 2 is pasted on the zinc oxide adhesive tape 1. The medicine 3 is applied to the magnetic suspension ring 2. A layer of the non-woven fabric 4 is attached onto the other surface of the magnetic suspension ring 2. A layer of the covering film 5 is attached to the outside of the non-woven fabric 4 to form the diabetes acupoint therapy sugar conversion paste 8. When in use, the covering film 5 is torn down to expose the non-woven fabric 4, and the exposed surface of the non-woven fabric 4 is flatly pasted on a corresponding acupoint of a human body and fixedly pasted on skin by the zinc oxide adhesive tape 1. After the magnetic suspension ring magnetizes the acupoint and the medicine, the diabetes acupoint therapy sugar conversion paste has a function of promoting quick absorption as well as a propulsive effect so that the diabetes can be cured early. The diabetes acupoint therapy sugar conversion paste is free of toxic and side effects; and the method is a simple and feasible good method for in-vitro treatment of the diabetes. The diabetes acupoint therapy sugar conversion paste has the advantages of low cost and using convenience in use and popularization, has great using value, and can be widely applied to places such as home, treatment rooms, hospitals, and the like.
Although Zambia has a generalized HIV epidemic, with approximately 13.3% of adults aged 15 to 49 living with HIV, the epidemic remains even more highly concentrated in key populations, including female sex workers (FSW). A particular concern for FSW is access to healthcare services, including HIV testing services. FSW face significant barriers to accessing healthcare. In other settings, evidence has suggested that stigma is a significant barrier to FSW seeking HIV testing. It is likely that similar mechanisms exist in Zambia. Evidence from Zambia has indicated that complex multilevel factors, such as stigmatization and harassment, contribute to vulnerability among FSW. User-controlled HIV prevention interventions that lead to empowerment of FSW may therefore be a powerful way to address the HIV epidemic in this key population.

Oral HIV self-testing consists of an oral swab kit that allows individuals to test for HIV in the privacy of their own homes whenever they want. The ease of use of HIV self-testing, that it can be done at any time, and that is completely private may make it an attractive alternative to currently-available HIV testing mechanisms for FSW in Zambia. HIV self-testing has generally been shown to be acceptable in a variety of populations, however evidence related to its uptake and acceptability remain sparse, especially among key populations and in Sub-Saharan Africa. This research will provide rigorous evidence of the uptake and efficacy of HIV self-testing for this population.

ZEST was designed to determine whether either direct distribution of HIV self-test kits via peer educators or distribution of HIV self-tests via coupons that participants can use to collect kits at collection points such as drug stores or health posts leads to better coverage of HIV testing and better awareness of HIV status. ZEST is a cluster-randomized trial in which peer educators recruit a small group of FSW participants, and the peer educator group is randomized to one of three study arms: 1) direct distribution of test kits, 2) fixed distribution of test kits, or 3) referral to standard of care HIV testing. The primary outcome is HIV testing in the past month measured at one and four months after the first peer educator visit (when the test kits or coupons are distributed in the intervention arms).
The purpose of this 8-week single center, randomized, open-label phase III trial to compare recombinant von Willebrand factor (rVWF, Vonvendi®)) plus tranexamic acid (TA, Cyclokapron®) vs. rVWF alone to prevent postpartum hemorrhage (PPH) in women with Von Willebrand disease (VWD). VWD is an inherited bleeding disorder that occurs in 1% of the population. It is caused by deficient or defective von Willebrand factor (VWF). Treatment at delivery is with VWF concentrate, based on U.S. and European guidelines, and as DDAVP, a non-VWF protein, is contraindicated as it may cause hyponatremia (low salt) and seizures due to fluid replacement at delivery. Yet, blood loss is 1.5-fold greater in VWD than non-VWD controls. The investigators believe this is due to physiologic (protective) fibrinolysis (clot breakdown) in the first 3 hours after delivery, which may protect controls from excess clotting after delivery, but which may increase bleeding in subjects with VWD. PPH a significant cause of maternal morbidity and mortality in women. PPH is defined as \>1000 ml within the first 24 hours of vaginal or cesarean delivery. PPH peaks in the first 2-3 hours postpartum, a time during which there is early activation of the fibrinolytic system, with a 2-fold increase TPA (tissue plasminogen activator). So while uterine atony is the major cause of PPH, accounting for 63% of PPH cases, but in 37% of cases, uterotonic agents fail.

TA is an anti-fibrinolytic therapy (prevents clot breakdown) which reduces bleeding and prevents clot breakdown in surgery, trauma, and in controls at delivery, if it is given within 3 hours of delivery. In the WOMAN trial, a large trial of over 10,000 women without bleeding disorders, TA was safe and effective in reducing PPH when given intravenously (in a vein) within 3 hours of vaginal or cesarean delivery. As TA is approved by the US. Food and Drug Administration (FDA) to treat and prevent bleeding in VWD, the investigators propose to study rVWF plus TA vs. VWF alone to reduce PPH in subjects with VWD. This is a pilot study to determine if recruitment, randomization, and study drug administration can be performed successfully, and shows preliminary safety and efficacy in subjects with VWD. rVWF (Vonvendi®) will be administered by intravenous infusion before delivery and on day 1 and day 2 postpartum. Tranexamic acid (Cyclokapron®) will be administered by intravenous infusion within 3 hours postpartum. Randomization will be at delivery to either rVWF at delivery and on day 1 and day 2 postpartum, plus TA within three hours postpartum; or rVWF alone at delivery and on day 1 and day 2 postpartum.
FIELD: veterinary virology. SUBSTANCE: vaccine strain "ЛТ" of cattle plague virus is grown on saiga kidney cell transplanted line in roller culture and inactivated with copper sulfate at final concentration 0.1-0.2% at 36-38 C for 22-26 hr. Inactivated vaccine is tested under laboratory and industrial conditions. Vaccine is harmless and nonreactogenic at its administration to rabbits, piglets, yaks and cattle and shows high antigenic and immunogenic properties. After two-fold vaccination (at 10-14 days interval) preparation causes formation of humoral immunity and resistance to infection with virulent strain of cattle plague in cattle. EFFECT: high effectiveness of vaccine. 1 tbl
An injection system (101) includes a fluid delivery system for moving an injection medium along a flow path for injection thereof into a subject. The system (or a separate extravasation detection system(131)) has an ultrasound transducer (133) for detecting ultrasound energy reflected from inside the subject and an ultrasound contrast enhancement system for introducing microbubbles into the subject during the injection. The microbubbles increase reflectivity of one or more fluids in the subject to ultrasound energy, facilitating extravasation detection. A needle (143) or injection line may be constructed to produce the microbubbles during the injection, for example. In use, ultrasound is directed into the subject. Microbubbles are introduced into the subject during the injection to increase reflectivity of one or more fluids in the subject (181) to ultrasound. Ultrasound energy reflected from inside the subject is detected to obtain information indicative of whether or not the injection is extravasating or non-extravasating.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. 

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 \~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).
The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
Procedure for preparing quinoline carboxylic acids, with formula I< IMAGE >(R = salient group R' = aliphatic or aromatic radical, R4 = F, H or acetoxy) which includes a) reaction by an acetophenone with acid chlorides or alkane carboxylic acid anhydrides in a solution of a boron compound in the alkane carboxylic acid, producing< IMAGE >b) reaction of the previous compound with acetic anhydride and trimethyl orthoformiate, producing a compound that is treated with an R'-NH2 amine, resulting in a new compound which is cyclised in the presence of platinum, nickel or palladium salts which act as a catalyst, and a base, producing< IMAGE >whose oxidation is the formula I compound.These quinoline carboxylic acids are valuable intermediaries for obtaining antibiotics.< IMAGE >Substd. quinoline carboxylic acids of formula (I) in which R is a salient gp. R1 is an aliphatic or aromatic gp. and R4 is F, H or acetoxy, are made by (a) reacting an acetophenone with an alkane carboxylic acid chloride or anhydride in a soln. of a boron cpd. in the alkane carboxylic acid to give (II) (b) reacting with acetic anhydride and trimethyl orthoformate and treating the prod. with an amine R1NH2 (c) cyclising in presence of Pt, Ni or Pd salts as catalyst and a base to give (III) and (d) oxidising to form cpd. of formula (I).
BACKGROUND: Recently, the development of advanced, noninvasive methods has allowed the study of respiratory function even in uncooperative infants. To date, there is still little data on the application of this technique in infants with suspected airway obstruction.
THE AIMS OF OUR STUDY WERE: - To evaluate the role of respiratory function testing (PFR) in the diagnosis and follow-up of infants with stridor - To evaluate the differences between patients with inspiratory stridor and expiratory stridor. - To evaluate the concordance between PFR and endoscopy.
METHODS: We enrolled infants aged < 1 year with a diagnosis of inspiratory and/or expiratory chronic stridor and a group of healthy controls. For each patient we performed PFR at diagnosis (T0) and for cases at follow-up, at 3 months (T1), 6 months (T2), 12 months (T3). At T0, all patients were classified according to a clinical score, and at follow-up, stature-ponderal growth was assessed. When clinically indicated, patients underwent bronchoscopy.
RESULTS: We enrolled 48 cases (42 diagnosed with inspiratory stridor and 6 expiratory stridor) and 26 healthy controls. At T0, patients with stridor had increased inspiratory time (p < 0.0001) and expiratory time (p < 0.001) than healthy controls and abnormal curve morphology depending on the type of stridor. At T0, patients with expiratory stridor had a reduced Peak expiratory flow (p < 0.023) and a longer expiratory time (p < 0.004) than patients with inspiratory stridor. We showed an excellent concordance between PFR and endoscopic examination (k = 0.885, p < 0.0001). At follow-up, we showed a progressive increase of the respiratory parameters in line with the growth.
CONCLUSIONS: PFR could help improve the management of these patients through rapid and noninvasive diagnosis, careful monitoring, and early detection of those most at risk.
PROBLEM TO BE SOLVED: To obtain the above new compound useful as a therapeutic and/or preventive agent for, e.g. hyperlipemia because of not only inhibiting squalene synthase but also being high in safety. SOLUTION: This new compound is a compound of formula I (R is H or methyl; X and Y are each H, or being combined into a single bond) or a salt thereof or a compound with the carboxyl group protected (for example, a compound of formula II). The compound of formula II or a salt thereof or a compound with the carboxyl group protected has the following physicochemical characteristics: character: acidic liposoluble white powder; molecular weight (FAB-MS method): 766; molecular formula: C41 H50 O14 ; etc. The compound of formula I is obtained by culturing Mollisia sp. SANK 10294 strain as a productive bacterium for the compound of formula I followed by collection from the cultured product.
BACKGROUND: Teicoplanin has been widely used in patients with infections caused by Staphylococcus aureus, especially for critically ill patients. The pharmacokinetics (PK) of teicoplanin vary between individuals and within the same individual. We aim to establish a prediction model via a combination of machine learning and population PK (PPK) to support personalized medication decisions for critically ill patients.
METHODS: A retrospective study was performed incorporating 33 variables, including PPK parameters (clearance and volume of distribution). Multiple algorithms and Shapley additive explanations were employed for feature selection of variables to determine the strongest driving factors.
RESULTS: The performance of each algorithm with PPK parameters was superior to that without PPK parameters. The composition of support vector regression, categorical boosting and a backpropagation neural network (7:2:1) with the highest R2 (0.809) was determined as the final ensemble model. The model included 15 variables after feature selection, of which the predictive performance was superior to that of models considering all variables or using only PPK. The R2, mean absolute error, mean squared error, absolute accuracy (±5 mg/L) and relative accuracy (±30%) of external validation were 0.649, 3.913, 28.347, 76.12% and 76.12%, respectively.
CONCLUSIONS: Our study offers a non-invasive, fast and cost-effective prediction model of teicoplanin plasma concentration in critically ill patients. The model serves as a fundamental tool for clinicians to determine the effective plasma concentration range of teicoplanin and formulate individualized dosing regimens accordingly.
This is a randomized, single-center, unblinded, pilot treatment study to evaluate pembrolizumab with or without lenvatinib as neoadjuvant therapy for RCC planned for surgical nephrectomy. Study objectives include the assessment of immunologic and histologic response measures following neoadjuvant therapy and their association with post-operative clinical outcomes. This trial will generate preliminary data on immune pharmacodynamic outcomes and tumor response for neoadjuvant pembrolizumab +/- lenvatinib and is not powered for comparison between the arms. Up to 33 participants will be enrolled to ensure 30 evaluable patients. Patients who receive neoadjuvant therapy and undergo nephrectomy are considered evaluable. The study will consist of 5 phases: 1) Study Screening; 2) Neoadjuvant Systemic Therapy; 3) Surgical Resection; 4) Adjuvant Systemic Pembrolizumab Therapy; and 5) Post-Treatment Follow-up. The total study participant duration, including participant follow-up across all 4 study phases, will be approximately 60 months.